文献速递临床试验与 GCP流行病学与生物统计

利用胜率改进肿瘤学中进入3期临床试验的决策

Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in Oncology.
PubMed 文献 · Stat Med · 2025-01-01

本文提出基于三终点胜率的决策框架,用于肿瘤学中是否进入3期临床试验的决策。作者认为胜率可解释为总生存平均风险比的倒数,并通过模拟研究和临床试验案例研究确认了该决策方法的性能。结论是胜率相比其他方法可改进进入3期临床试验的决策。

要点

  • 提出基于三终点胜率的决策框架用于肿瘤学3期试验决策。
  • 胜率可解释为总生存平均风险比的倒数用于决策。
  • 模拟研究和临床试验案例研究确认了决策方法的性能。

核心结论

  • 胜率相比其他方法可改进进入3期临床试验的决策。

研究设计与样本

  • 使用模拟研究和一项临床试验案例研究确认决策方法的性能。
  • 描述使用多状态疾病模型模拟相关的患者水平肿瘤学终点。

主要发现

  • 胜率可解释为总生存平均风险比的倒数用于决策。
  • 该多状态模型可为测试分析方法性能提供临床现实数据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Making good decisions about whether to commit-to-phase 3 clinical trials is challenging. This is especially true in oncology because the relationships between the registration endpoint, overall survival, and endpoints such as progression-free survival and confirmed objective response are often poorly understood. We present a framework for decision-making based on a three-endpoint win odds. We discuss properties of the win odds and suggest that it can be interpreted, for decision-making, as the reciprocal of an average hazard ratio for overall survival. We confirm the performance of the decision-making method using simulation studies and a clinical trial case study. As part of this work, we describe the simulation of correlated patient-level oncology endpoints using a multi-state model of disease. This model can provide clinically realistic data for testing the performance of analysis methods. We conclude that the win odds can improve commit-to-phase-3 decision-making compared with other methods.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Hartley BF, Drury T, Di Pace B, et al. Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in Oncology. Stat Med. 2025. PMID: 39950312. doi:10.1002/sim.70024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。